Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Clin Trials. 2021 Jan 10;18(2):237–244. doi: 10.1177/1740774520982315

Table 1.

Baseline Characteristics of Study Participants and Partners, Resveratrol Trial (N=119)

Characteristic Study Patients
Age, mean (SD) 71.3 (8.1)
 65+ years old, n (%) 93 (78.2)
Females, n (%) 68 (57.1)
Race / Ethnicity, n (%)
 White, Non-Latino 108 (90.8)
 African American, Non-Latino 7 (5.9)
 Othera 4 (3.2)
Hispanic or Latino Ethnicity, n (%)) 1 (0.8)
Education, n (%)
 High School/GED or Less 31 (26.1)
 Some College or 2-year Degreeb 26 (21.0)
 4-year College Degree or beyond 62 (52.1)
ADCS - Activities of Daily Living Inventory, median (IQR) 65 (16)
ADAS Cognitive Behavior Score, mean (SD) 24.5 (9.5)
NPI,c median (IQR) 8 (12)
APOE genotype, n (%)
 Noncarrier 38 (31.9)
 Heterozygote 59 (49.6)
 Homozygote 22 (18.5)
Study Partners
Female,d n (%) 63 (52.9)
Spousal relationship to study patient, n (%) 93 (78.2)
Resides with study patient, e n (%) 103 (86.6)
Hours per week spent with patient, median (IQR) 130 (98)

Note. Column percentages may not total 100 due to rounding. SD = standard deviation. ADCS = Alzheimer’s Disease Cooperative Study, ADAS = Alzheimer’s Disease Assessment Scale, NPI = Neuropsychiatric Inventory, IQR = interquartile range.

a

Category includes those who identified as Asian and American Indian or Alaskan Native.

b

4-year college, master’s, doctorate, or professional degrees.

c

Includes one person whose total score was missing one domain score.

d

Sex/gender is unknown for 5 study partners.

e

Includes one person who lives half-time with participant.